Johannes Breyer

Dr. Johannes Breyer

Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NKNiklas Klümper
Niklas Klümper
DRDamian J. Ralser
Damian J. Ralser
Jörg EllingerJörg Ellinger
Jörg Ellinger
FRFlorian Roghmann
Florian Roghmann
JAJulia Albrecht
Julia Albrecht
Markus EcksteinMarkus Eckstein
Markus Eckstein
Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous NECTIN-4 expression is assumed. Our objective was to determine the prevalence of membranous NECTIN-4 protein expression in primary tumors (PRIM) and patient-matched distant metastases (MET). Experimental Design: Membranous NECTIN-4 protein expression was measured (H-score) by IHC in PRIM and corresponding MET (N = 137) and in a multicenter EV-treated cohort (N = 47). Progression-free survival (PFS) after initiation of EV treatment was assessed for the NECTIN-4–negative/weak (H-score 0–99) versus moderate/strong (H-score 100–300) subgroup. The specificity of the NECTIN-4 IHC staining protocol was validated by establishing CRISPR-Cas9–induced polyclonal NECTIN-4 knockouts. Results: In our cohort, membranous NECTIN-4 expression significantly decreased during metastatic spread (Wilcoxon matched pairs P < 0.001; median H-score = 40; interquartile range, 0–140), with 39.4% of MET lacking membranous NECTIN-4 expression. In our multicenter EV cohort, absence or weak membranous NECTIN-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001). Conclusions: Membranous NECTIN-4 expression is frequently decreased or absent in mUC tissue. Of note, the clinical benefit of EV strongly depends on membranous NECTIN-4 expression. Thus, our results are of highest clinical relevance and argue for a critical reconsideration of the current practice and suggest that the NECTIN-4 receptor status should be determined (ideally in a metastatic/progressive lesion) before initiation of EV. See related commentary by Aggen et al., p. 1377


10 January 2017 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
OCon behalf of the BRIDGE Consortium
on behalf of the BRIDGE Consortium
JBJohannes Breyer
Johannes Breyer
RWRalph M. Wirtz
Ralph M. Wirtz
WOWolfgang Otto
Wolfgang Otto
PEPhilipp Erben
Philipp Erben
AHArndt Hartmann
Arndt Hartmann

17 November 2017 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
JBJohannes Breyer
Johannes Breyer
RWRalph M. Wirtz
Ralph M. Wirtz
WOWolfgang Otto
Wolfgang Otto
PEPhilipp Erben
Philipp Erben
TWThomas Stefan Worst
Thomas Stefan Worst
AHArndt Hartmann
Arndt Hartmann

22 September 2015 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
JBJohannes Breyer
Johannes Breyer
MGMichael Gierth
Michael Gierth
SSSanzhar Shalekenov
Sanzhar Shalekenov
AAAtiqullah Aziz
Atiqullah Aziz
JSJulius Schäfer
Julius Schäfer
WOWolfgang Otto
Wolfgang Otto

Verified
Journal Article
Open access
PDF file
Markus EcksteinMarkus Eckstein
Markus Eckstein
RWRalph M. Wirtz
Ralph M. Wirtz
MGMatthias Gross-Weege
Matthias Gross-Weege
JBJohannes Breyer
Johannes Breyer
WOWolfgang Otto
Wolfgang Otto
PEPhilipp Erben
Philipp Erben
Recently, muscle-invasive bladder cancer (MIBC) has been subclassified by gene expression profiling, with a substantial impact on therapy response and patient outcome. We tested whether these complex molecular subtypes of MIBC can be determined by mRNA detection of keratin 5 (KRT5) and keratin 20 (KRT20). Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) was applied to quantify gene expression of KRT5 and KRT20 using TaqMan®-based assays in 122 curatively treated MIBC patients (median age 68.0 years). Furthermore, in silico analysis of the MD Anderson Cancer Center (MDACC) cohort (GSE48277 + GSE47993) was performed. High expression of KRT5 and low expression of KRT20 were associated with significantly improved recurrence-free survival (RFS) and disease-specific survival disease specific survival (DSS: 5-year DSS for KRT5 high: 58%; 5-year DSS for KRT20 high: 29%). KRT5 and KRT20 were associated with rates of lymphovascular invasion and lymphonodal metastasis. The combination of KRT5 and KRT20 allowed identification of patients with a very poor prognosis (KRT20+/KRT5−, 5-year DSS 0%, p < 0.0001). In silico analysis of the independent MDACC cohorts revealed congruent results (5-year DSS for KRT20 low vs. high: 84% vs. 40%, p = 0.042). High KRT20-expressing tumors as well as KRT20+/KRT− tumors were significantly enriched with aggressive urothelial carcinoma variants (micropapillary, plasmacytoid, nested).